Barry, Abbie http://orcid.org/0000-0002-3859-3660
Olsson, Sten http://orcid.org/0000-0002-6078-0649
Minzi, Omary
Bienvenu, Emile http://orcid.org/0000-0002-1555-7376
Makonnen, Eyasu http://orcid.org/0000-0002-9259-5288
Kamuhabwa, Appolinary
Oluka, Margaret
Guantai, Anastasia
Bergman, Ulf
van Puijenbroek, Eugène http://orcid.org/0000-0002-2236-1398
Gurumurthy, Parthasarathi http://orcid.org/0000-0002-5997-1157
Aklillu, Eleni http://orcid.org/0000-0002-9788-0790
Funding for this research was provided by:
European and Developing Countries Clinical Trials Partnership (CSA2016S-1618)
Article History
First Online: 9 January 2020
Compliance with Ethical Standards
:
: Abbie Barry, Sten Olsson, Omary Minzi, Emile Bienvenu, Eyasu Makonnen, Appolinary Kamuhabwa, Margaret Oluka, Anastasia Guantai, Ulf Bergman, Eugène van Puijenbroek, Parthasarathi Gurumurthy, and Eleni Aklillu have no conflict of interest.
: This study was conducted as part of the Pharmacovigilance infrastructure and post-marketing surveillance system capacity building for regional medicine regulatory harmonization in East Africa (PROFORMA) project funded by the European & Developing Countries Clinical Trials Partnership (EDCTP) 2 program supported by the European Union (Grant number CSA2016S-1618) and the Swedish International Development Cooperation Agency (Sida).
: All data generated or analyzed during this study are included in this published article.